Other
Income Taxes Paid, Net
Vertex Pharmaceuticals Income Taxes Paid, Net decreased by 78.9% to $82.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 55.4%, from $184.40M to $82.30M. Over 4 years (FY 2021 to FY 2025), Income Taxes Paid, Net shows an upward trend with a 34.7% CAGR.
Analysis
StatementIncome Statement
SectionOther
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
Metric ID:
other_income_taxes_paid_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $223.70M | $147.10M | $94.80M | $85.00M | $393.30M | $361.80M | $217.70M | $419.33M | $419.33M | $419.33M | $419.33M | $34.80M | $497.00M | $278.50M | $271.80M | $184.40M | $513.30M | $479.60M | $389.40M | $82.30M |
| QoQ Change | — | -34.2% | -35.6% | -10.3% | +362.7% | -8.0% | -39.8% | +92.6% | +0.0% | +0.0% | +0.0% | -91.7% | >999% | -44.0% | -2.4% | -32.2% | +178.4% | -6.6% | -18.8% | -78.9% |
| YoY Change | — | — | — | — | +75.8% | +146.0% | +129.6% | +393.3% | +6.6% | +15.9% | +92.6% | -91.7% | +18.5% | -33.6% | -35.2% | +429.9% | +3.3% | +72.2% | +43.3% | -55.4% |
Range$34.80M – $513.30M
CAGR-19.0%
Avg YoY Growth+75.7%
Median YoY Growth+30.9%
Current Streak3 quarters decline
Income Taxes Paid, Net at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's income taxes paid, net?
- Vertex Pharmaceuticals (VRTX) reported income taxes paid, net of $82.30M in Q1 2026.
- How has Vertex Pharmaceuticals's income taxes paid, net changed year-over-year?
- Vertex Pharmaceuticals's income taxes paid, net decreased by 55.4% year-over-year, from $184.40M to $82.30M.
- What is the long-term trend for Vertex Pharmaceuticals's income taxes paid, net?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's income taxes paid, net has grown at a 34.7% compound annual growth rate (CAGR), from $476.30M to $1.57B.